CRO Services
Biomarker Analysis for Clinical Trials
CommercialActive
Key Facts
About BetaSense
BetaSense is an early-stage diagnostics company developing a proprietary structural biomarker detection platform called iRS. The technology uses infrared spectroscopy to identify misfolded proteins in biofluids like serum and CSF, demonstrating high diagnostic accuracy (AUC >0.93) for Parkinson's disease. Founded in 2025, the company operates as a CRO lab, collaborates with pharmaceutical partners, and is positioning its platform for clinical diagnostics and drug development support. Its goal is to shift neurodegenerative disease management to pre-symptomatic stages.
View full company profile